Biopsy-based study for alcohol and metabolic liver disease
Part of Cancer, Digestive system clinical trials.
This trial studies people with liver disease linked to alcohol use or metabolic syndrome (a cluster of conditions like weight gain and insulin resistance). It uses recent standard-of-care liver biopsy results to better understand these chronic liver problems and how they relate to cancer risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must live in France and be covered by French social security
- You must be age 18 or older and able to understand the study and sign consent
- You must have had a liver biopsy in the last 3 months (for a suspected liver issue/cancer or abnormal liver tests/ultrasound fat)
- If you drink alcohol, your intake must fit one of the study’s alcohol limits (or include binge drinking for the alcohol group)
- You must not have had blood-thinning cancer medicines for liver cancer in the last 6 months
- You must not have certain other liver diseases or major immune/organ conditions (see screening questions below)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study builds a research library of biological samples (like tissue and blood) from people with chronic liver disease. It aims to create better lab and preclinical models of tumors and long-term liver problems, which may help future treatments.
This study is looking for new ways to detect liver scarring (fibrosis) in people with fatty liver disease (NAFLD, NASH, MASLD, or MASH). If you qualify, you will give a blood sample to help identify biomarkers that could replace biopsies.
This study compares new, non-invasive tests to standard liver biopsy for diagnosing fatty liver disease in people with type 2 diabetes or other signs of metabolic syndrome. It aims to see if these simpler tests can replace biopsies.
This study looks at what drives non-alcoholic fatty liver disease and how it affects the body, including immune-related changes. You may be invited if you have confirmed fatty liver disease or, alternatively, if you are a healthy person with no liver disease.
This study looks at integrated diagnostic tests to find early liver problems sooner. It may help you (if referred to the community liver clinic) get more timely information about what’s going on.
This study collects health information from people with non-alcoholic fatty liver disease (NAFLD), a condition where fat builds up in the liver. It aims to learn more about the disease to improve future care.
Hear when a new Alcohol-related Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.